Approximately 70% of the original study was announced at the domestic first imitation price of Sora non-nylon

Recently, according to the Inner Mongolia Autonomous Region pharmaceutical centralized procurement network issued a notice that Jiangxi Shanxiang Pharmaceutical Toluene Sulfini tablets (specification: 0.2g x 60 tablets) to give supplementary hanging network, the purchase price of 3990.00 yuan / box, September 5, 2020 officially implemented.
It is understood that Solafini is an oral multi-target, multi-kinase inhibitor developed by Bayer, which can block tumor angiogenesphage by inhibiting endothoste growth factor subjects (VEGFR) and plateiac-based growth factors (PDGFRs), and can also inhibit tumor cell proliferation by blocking the transmission of Raf/MEK/ERK signals to the path to inhibit tumor cell proliferation, thus playing a double inhibitory, multi-targeting anti-cancer effect.
the drug has been approved for the treatment of kidney cancer, hepatocellular carcinoma, local advanced or metastatic radioactive iodine (RAI) reassotic differentiated thyroid cancer.
is mainly used in the treatment of hepatocellular carcinoma, renal cell carcinoma and thyroid cancer.
was first approved by the FDA in December 2005 for the treatment of advanced kidney cancer, in 2007 in Europe, the United States approved the treatment of hepatocellular carcinoma, in September 2006 by the National Drug Administration Approved to enter the Chinese market, the commodity is Dojime, for the treatment of non-surgical patients with advanced liver cancer, Soraphini is the first systematic treatment drug with clear evidence to improve the survival of patients with advanced liver cancer, but also the domestic liver cell carcinoma patients clinical first-line standard drug.
, which successfully entered health care negotiations in 2017 and renewed its contract in 2019, currently pays 95 yuan per tablet (0.2g) and a box (size: 0.2g x 60 pieces) costs about 5,700 yuan.
In August this year, Qingfeng Pharmaceutical Group's Jiangxi Shanxiang Pharmaceutical Co., Ltd. developed four classes of generic drug toluene sulfonate soraphini (commodity name: Ligeste) was approved for listing, which is also the first approved soraphine generic drugs in China, and as if through generic drug consistency evaluation.
, according to the published online price, generic drugs are about 70% of the original research.
week after the approval of Jiangxi Shanxiang Pharmaceuticals, Chongqing drugmaker Sorafini generics became the second to be approved, and its price has not yet been announced.
for Bayer, the competition will intensify and market share will be split as more generics are approved for sale.
meters of intranet data show that in recent years, Sorafeini tablets in China's public medical institutions terminal sales increased year by year, due to its entry into the health care negotiation directory and the newly approved listing, sales in 2018 has been greatly improved, sales revenue of 1.03 billion yuan, an increase of 32.08 percent year-on-year, and other data show that in 2019 Sorafeini domestic sales of about 1.2 billion yuan.
However, with Jiangxi Shanxiang Pharmaceuticals and Chongqing Pharmaceutical Friends' products have been approved, the monopoly position of the original research soraphini was broken, some analysts said, this is likely to directly promote the original research prices continue to decline, channels continue to sink, and may even be collected, Soraphini is expected to become the basic drug for liver cancer treatment, and thus cover more confirmed patients.
addition, according to the Medical Rubik's Cube database, Shi Medicine Europe, Zhengda Tianqing, Yabao Pharmaceuticals, Furen Pharmaceuticals have also been in the layout of research and development of Solafuni.